» Articles » PMID: 22697293

High Survivin Expression As a Risk Factor in Patients with Anal Carcinoma Treated with Concurrent Chemoradiotherapy

Overview
Journal Radiat Oncol
Publisher Biomed Central
Specialties Oncology
Radiology
Date 2012 Jun 16
PMID 22697293
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate the prognostic value of survivin expression in pretreatment specimens from patients with anal cancer treated with concurrent 5-FU and mitomycin C-based chemoradiation (CRT).

Material And Methods: Immunohistochemical staining for survivin was performed in pretreatment biopsies of 62 patients with anal carcinoma. Survivin expression was correlated with clinical and histopathological characteristics as well as local failure free- (LFFS), distant metastases free- (DMFS), cancer specific- (CSS), and overall survival (OS).

Results: Survivin staining intensity was weak in 10%, intermediate in 48% and intense in 42% of the patients. No association between survivin expression and clinicopathologic factors (tumor stage, age and HIV status) could be shown. In univariate analysis, the level of survivin staining was significantly correlated with DMFS (low survivin vs. high survivin: 94% vs. 74%, p = 0.04). T-stage, N-stage and the tumor grading were significantly associated with OS and CSS and with DMFS and LFFS, respectively. In multivariate analysis, survivin was confirmed as independent prognostic parameter for DMFS (RR, 0.04; p = 0.02) and for OS (RR, 0.27; p = 0.04).

Conclusion: Our results demonstrated that the level of pretreatment survivin is correlated with the clinical outcome in patients with anal carcinoma treated with concurrent CRT. Further studies are warranted to elucidate the complex role of survivin for the oncologic treatment and to exploit the protein as a therapeutic target in combined modality treatment of anal cancer.

Citing Articles

Transcriptome and microbiome-immune changes across preinvasive and invasive anal cancer lesions.

Lacunza E, Fink V, Salas M, Gun A, Basiletti J, Picconi M JCI Insight. 2024; 9(16).

PMID: 39024554 PMC: 11343604. DOI: 10.1172/jci.insight.180907.


Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.

Ge C, Li R, Song H, Geng T, Yang J, Tan Q BMC Cancer. 2017; 17(1):884.

PMID: 29268708 PMC: 5740508. DOI: 10.1186/s12885-017-3859-3.


Peripheral Leukocytosis Is Inversely Correlated with Intratumoral CD8+ T-Cell Infiltration and Associated with Worse Outcome after Chemoradiotherapy in Anal Cancer.

Martin D, Rodel F, Winkelmann R, Balermpas P, Rodel C, Fokas E Front Immunol. 2017; 8:1225.

PMID: 29085358 PMC: 5649213. DOI: 10.3389/fimmu.2017.01225.


Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells.

Jenkins R, Bandera Y, Daniele M, Ledford L, Tietje A, Kelso A Biomater Sci. 2016; 4(4):614-26.

PMID: 26845086 PMC: 4803599. DOI: 10.1039/c5bm00580a.


Expression of survivin and its four splice variants in colorectal cancer and its clinical significances.

Ge Q, Li Y, Nie Y, Zuo W, Du Y Med Oncol. 2013; 30(2):535.

PMID: 23494669 DOI: 10.1007/s12032-013-0535-6.


References
1.
Mehrotra S, Languino L, Raskett C, Mercurio A, Dohi T, Altieri D . IAP regulation of metastasis. Cancer Cell. 2010; 17(1):53-64. PMC: 2818597. DOI: 10.1016/j.ccr.2009.11.021. View

2.
Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T . Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res. 2005; 65(11):4881-7. DOI: 10.1158/0008-5472.CAN-04-3028. View

3.
Rodel C, Haas J, Groth A, Grabenbauer G, Sauer R, Rodel F . Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys. 2003; 55(5):1341-7. DOI: 10.1016/s0360-3016(02)04618-7. View

4.
Indinnimeo M, Cicchini C, Stazi A, Limiti M, Ghini C, Mingazzini P . Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res. 2001; 19(4):471-5. View

5.
Chakravarti A, Zhai G, Zhang M, Malhotra R, Latham D, Delaney M . Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene. 2004; 23(45):7494-506. DOI: 10.1038/sj.onc.1208049. View